Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AXSM – Axsome Therapeutics, Inc.

Float Short %

8.95

Margin Of Safety %

Put/Call OI Ratio

0.6

EPS Next Q Diff

0.32

EPS Last/This Y

2.36

EPS This/Next Y

4.42

Price

118.6

Target Price

175.67

Analyst Recom

1.05

Performance Q

13.57

Relative Volume

1.15

Beta

0.52

Ticker: AXSM




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25AXSM100.830.672.2919431
2025-07-28AXSM100.420.710.6420065
2025-07-29AXSM100.370.711.3720247
2025-07-30AXSM101.250.710.4620301
2025-07-31AXSM101.310.7112.4720383
2025-08-01AXSM103.040.760.0521093
2025-08-04AXSM106.580.740.2221574
2025-08-05AXSM103.550.740.2421772
2025-08-06AXSM103.290.730.1422180
2025-08-07AXSM104.290.720.1222299
2025-08-08AXSM104.80.720.0522428
2025-08-11AXSM1040.710.1222452
2025-08-12AXSM105.240.710.0822496
2025-08-13AXSM109.350.730.3922160
2025-08-14AXSM108.750.720.1222443
2025-08-15AXSM109.210.720.1022460
2025-08-18AXSM111.140.750.9820165
2025-08-19AXSM111.710.660.9220081
2025-08-20AXSM116.970.660.1420277
2025-08-21AXSM117.150.630.0220888
2025-08-22AXSM118.690.600.1621572
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25AXSM100.8336.1101.9-3.67
2025-07-28AXSM100.2536.195.9-3.67
2025-07-29AXSM100.4136.194.9-3.67
2025-07-30AXSM101.2636.193.2-3.67
2025-07-31AXSM101.3835.194.7-3.67
2025-08-01AXSM103.0235.191.9-3.80
2025-08-04AXSM106.5434.988.8-3.81
2025-08-05AXSM103.5934.999.8-3.81
2025-08-06AXSM103.2934.464.4-3.81
2025-08-07AXSM104.3234.462.1-3.81
2025-08-08AXSM104.8034.687.6-3.66
2025-08-11AXSM103.9134.689.6-3.66
2025-08-12AXSM105.2135.186.5-3.66
2025-08-13AXSM109.3935.182.2-3.66
2025-08-14AXSM108.7235.189.3-3.66
2025-08-15AXSM109.1835.187.7-3.63
2025-08-18AXSM111.1135.185.7-3.63
2025-08-19AXSM111.2935.088.1-3.63
2025-08-20AXSM117.0535.080.4-3.63
2025-08-21AXSM117.0435.088.3-3.63
2025-08-22AXSM118.6035.086.4-3.63
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25AXSM-1.43-2.828.98
2025-07-28AXSM-1.43-3.208.98
2025-07-29AXSM-1.43-3.208.98
2025-07-30AXSM-1.43-3.208.98
2025-07-31AXSM-1.43-3.208.98
2025-08-01AXSM-1.43-3.208.98
2025-08-04AXSM-1.43-3.728.98
2025-08-05AXSM-1.43-3.728.98
2025-08-06AXSM-1.43-3.728.98
2025-08-07AXSM-1.41-3.728.85
2025-08-08AXSM-1.41-3.728.85
2025-08-11AXSM-1.41-3.608.85
2025-08-12AXSM-1.41-3.608.96
2025-08-13AXSM-1.41-3.608.96
2025-08-14AXSM-1.41-3.608.96
2025-08-15AXSM-1.24-3.608.96
2025-08-18AXSM-1.24-4.018.95
2025-08-19AXSM-1.25-4.018.95
2025-08-20AXSM-1.25-4.018.95
2025-08-21AXSM-1.25-4.018.95
2025-08-22AXSM-1.25-4.018.95
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.92

Avg. EPS Est. Current Quarter

-0.87

Avg. EPS Est. Next Quarter

-0.6

Insider Transactions

-1.25

Institutional Transactions

-4.01

Beta

0.52

Average Sales Estimate Current Quarter

164

Average Sales Estimate Next Quarter

186

Fair Value

Quality Score

30

Growth Score

39

Sentiment Score

77

Actual DrawDown %

14.8

Max Drawdown 5-Year %

-77

Target Price

175.67

P/E

Forward P/E

104.61

PEG

P/S

11.95

P/B

80.79

P/Free Cash Flow

EPS

-5.07

Average EPS Est. Cur. Y​

-3.63

EPS Next Y. (Est.)

0.79

Target Price Estimates Raised

Target Price Estimates Lowered

1

Profit Margin

-49.88

Relative Volume

1.15

Return on Equity vs Sector %

-362.6

Return on Equity vs Industry %

-349.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

86.4
Axsome Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 846
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York.
stock quote shares AXSM – Axsome Therapeutics, Inc. Stock Price stock today
news today AXSM – Axsome Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AXSM – Axsome Therapeutics, Inc. yahoo finance google finance
stock history AXSM – Axsome Therapeutics, Inc. invest stock market
stock prices AXSM premarket after hours
ticker AXSM fair value insiders trading